Dyne Therapeutics’ DYNE-101 shows positive results in phase 1/2 ACHIEVE study. Read why DYN stock may rise with FDA approval and a $2.78B market opportunity.

In this analysis presented at the American Academy of Dermatology annual meeting, serious adverse events were low, unrelated ...

(CNN) — President Donald Trump’s pick to lead the US Food and Drug Administration told senators in a tense confirmation hearing Thursday that, if confirmed as FDA commissioner, he plans to evaluate ...